Purple Biotech Stock (NASDAQ:PPBT), Trade Ideas

Purple Biotech

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

AAGR

ACRX

BMEA

CRVS

EFTR

ISUN

NAAS

NUZE

NXTP

ONTX

PCSA

PPBT

XFOR

Shares of  Green Giant Inc.  (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering.

Green Giant shares dipped 37.1% to $0.1599 in pre-market trading.

Here are some other stocks moving in pre-market trading.

Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket

ADIL

ASTI

BANL

BDRX

CING

CRKN

CVKD

DTST

ELOX

ENOB

GDTC

HCTI

ICCC

PIXY

PRFX

SILK

VVOS

WLGS

Gainers


	Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares surged 131.6% to $4.03 in pre-market trading after gaining 15% on Tuesday.


Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket

Biotech

Health Care

Initiation

Analyst Ratings

General

Purple Biotech&#39;s Assets Are First In Class For Solid Tumor Treatment, Analyst Says

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech Ltd

<a href="https://www.chicagofed.org/publications/speeches/2024/apr-19-society-advancing-business-editing-writing" title="https://www.chicagofed.org/publications/speeches/2024/apr-19-society-advancing-business-editing-writing">https://www.chicagofed.org/publications/speeches/2024/apr-19-society-advancing-business-editing-writing</a>

Macro Economic Events

Economics

Federal Reserve

Fed's Goolsbee Says If You Hold At This Level Of Restrictiveness For Too Long, You Will Have Start Thinking About The Impact On Jobs; The Policy Tradeoffs Are Harder This Year

Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) with a Overweight.

Reiteration

CMPS

Cantor Fitzgerald Reiterates Overweight on Compass Pathways

<a href="https://www.chicagofed.org/publications/speeches/2024/apr-19-society-advancing-business-editing-writing">https://www.chicagofed.org/publications/speeches/2024/apr-19-society-advancing-business-editing-writing</a>
&nbsp;

Fed's Goolsbee Says We Have Done Great On The Employment Mandate But We Have Not Succeeded On The Inflation Mandate

U.S. stocks were mixed, with the Nasdaq Composite falling over 100 points on Friday.
Shares of Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) rose during Friday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/FITB/earnings">quarterly financial results</a>.
Fifth Third Bancorp posted adjusted earnings of 76 cents per share, beating market estimates of 70 cents per share. The company's sales came in at $2.100 billion versus expectations of $2.086 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Fifth Third Bancorp shares gained 4.2% to $35.67 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Mobile-health Network Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares jumped 20.2% to $24.53.</li>
<li>Metropolitan Bank Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCB#NYSE">MCB</a>) rose 19% to $39.40 after the company reported better-than-expected first-quarter financial results.</li>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) climbed 12.2% to $4.03.</li>
<li>Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) shares rose 9.7% to $12.03 following reports suggesting Sony is in talks with Apollo to join a bid for the company.</li>
<li>Cohen &amp; Steers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNS#NYSE">CNS</a>) gained 8.1% to $71.48 after it was announced the stock will join the S&amp;P SmallCap 600.</li>
<li>Tellurian Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TELL#NYSE">TELL</a>) shares jumped 7.8% to $0.4172.</li>
<li>Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) gained 6.6% to $13.75. Alvotech inked a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the US market.</li>
<li>Bar Harbor Bankshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHB#NYSE">BHB</a>) climbed 5.6% to $25.20 following upbeat quarterly earnings.</li>
<li>Nuvation Bio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) rose 5.2% to $2.7150.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) shares rose 4.8% to $3.0589. Wedbush, on Thursday, slashed its price target on the stock to $4 on Thursday.</li>
<li>Community Health Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) gained 4.7% to $2.9099. Community Health Systems announced an agreement to sell Cleveland, Tennessee, Hospital to Hamilton Health Care System for $160 million in cash.</li>
</ul>
Read More: <a href="https://www.benzinga.com/news/24/04/38334217/netflix-to-rally-around-31-here-are-10-top-analyst-forecasts-for-friday">Netflix To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Friday</a>

Intraday Update

ALVO

FITB

HUMA

MNDR

NUVB

PARA

TELL

Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday

Cannabis is a "competitive industry," and those looking to build their business should "embrace it," says Kevin Hart, founder and CEO of Green Check Verified, a leader in banking solutions for the cannabis industry.
To get the much-needed capital, all you need to do is not be afraid of the competitive environment, Hart told those gathered at the <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a> in Florida on Tuesday.
"There&#8217;s access to financial and business services at your fingertips," Hart said, adding, "You just have to be prepared to share some information."
For Adam Stettner, founder and CEO of FundCanna, &#8220;that information is how the money will be used." Stetter joined Hart and two other industry experts, Ryan Himmel, VP and head of strategic partnerships at LeafLink and Sahar Ayinehsazian, a partner in Vicente LLP&#8216;s Los Angeles office. The panel was moderated by Jeanne M. Sullivan, chief investment officer at Arcview Ventures.
<figure class="wp-block-image aligncenter size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19071159/2231044_CCCFloridaGIF_V2_031124-1-41.gif" alt="" class="wp-image-299701" /></a></figure>
The panelist discussed the complexities of banking for cannabis businesses, outlining best practices for financial fitness and strategies for achieving banking access.
As the head of the company that provides access to flexible capital for the cannabis industry, Stettner is most interested in how the "money will be applied and what the repayment terms look like,' while thinking about"what the loopholes are," in terms of the borrows financial fitness and strength.
<h3 class="wp-block-heading" id="h-what-does-being-fit-mean">What Does Being Fit Mean?</h3>
When assessing if someone is fit as a borrower, the main parameter is cash flow, he said.
See also: <a href="https://www.benzinga.com/markets/cannabis/24/03/37747058/new-financing-solutions-change-the-game-for-the-cannabis-industry">New Financing Solutions Change The Game For The Cannabis Industry</a>
"It&#8217;s very hard to determine how you qualify for repayment and how that repayment will impact your business if you don&#8217;t have a baseline of revenue from which to calculate," Stettner explained.
Vicente LLP&#8217;s Ayinehsazian said being fit for banking means your business is at the "pinnacle of fitness."
Why? That's due to banking being closely related to the many different aspects of a business, including being compliant with operations, running smoothly with corporate records being in order, she explained.
"You&#8217;re also fit for a surprise visit from a regulator, you&#8217;re also fit for a potential investor or a potential lender to come in and take a look at you," Ayinehsazian noted.
<h3 class="wp-block-heading" id="h-know-what-you-are-dealing-with">Know What You Are Dealing With</h3>
She also emphasized cannabis operators need to understand the price paid for capital and the potential ‘ripple effects' that come with it.
"There&#8217;s no such thing as a free lunch," Ayinehsazian said. "So if you are able to access capital, but it seems a little bit too good to be true, it probably is a little bit too good to be true."
LeafLink&#8217;s Himmel, representing the industry&#8217;s wholesale platform that focuses on cannabis businesses being more fit as it relates to banking, has a similar opinion.
One of the most important aspects of any company's financial fitness is knowing how to rationalize tools at its disposal and making data-driven decisions, he said.
Cannabis businesses need to "have the ability to manage inventory," to avoid "causing bad unhealthy behavior such as channel stuffing in the market."
"We cannot be in a situation in a year from now, where we still have states where there&#8217;s three years worth of inventory at the wholesale level," Himmel continued.
Instead, he is proposing more consolidation and providing cannabis operators with more value in a single unified experience to help them be "better fit to get banking services."
After all, cannabis operators don&#8217;t want to be burdened with regulations on the financial side of their businesses, as Green Check&#8217;s Hart noted.
To address that, Green Check is working on providing availability and creating that "frictionless environment so you don&#8217;t injure yourself and you know have problems of having to go out and get new bank accounts and everything." 
Now read: <a href="https://www.benzinga.com/markets/cannabis/24/04/38278653/cannabis-banking-reform-closer-than-ever-d-c-insiders-tell-benzinga-conference-cannabis-etf-spik">Cannabis Banking Reform &#8216;Closer Than Ever,&#8217; D.C. Insiders Tell Benzinga Conference: Cannabis ETF On The Move Tuesd</a><a href="https://www.benzinga.com/markets/cannabis/24/04/38278653/cannabis-banking-reform-closer-than-ever-d-c-insiders-tell-benzinga-conference-cannabis-etf-spik">ay</a>
Photo by Jean Laurenceau

Cannabis

Financing

Events

Exclusives

EXCLUSIVE: Banking-Fit Means Your Cannabis Business Is At The 'Pinnacle Of Fitness,' Experts Explain At Benzinga Conference

Barclays analyst Brandt Montour maintains Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) with a Overweight and raises the price target from $204 to $216.

Price Target

Barclays Maintains Overweight on Hilton Worldwide Holdings, Raises Price Target to $216

Fed's Goolsbee Says the 'Golden Path' Is More Difficult For 2024

Goldman Sachs analyst Matthew Sykes maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Neutral and lowers the price target from $7 to $2.5.

PACB

Goldman Sachs Maintains Neutral on Pacific Biosciences, Lowers Price Target to $2.5

In the fast-paced realm of digital entertainment, the battle for supremacy between streaming giants Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) and Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) has captured the attention of investors and <a href="https://www.benzinga.com/quote/DIS/news">industry observers alike. </a>
As the media and entertainment market surges towards a projected value of $40.36 billion by 2029 (per Mordor Intelligence <a href="https://www.mordorintelligence.com/industry-reports/media-and-entertainment-market-landscape">data</a>), the competition intensifies, fueled by evolving consumer preferences and technological advancements.
Streaming platforms such as Netflix and Disney have emerged as key players in this landscape, offering consumers unparalleled convenience and a diverse array of content. With a projected compound annual growth rate (CAGR) of 7.8%, the industry is poised for exponential expansion in the coming years.
<h1 class="wp-block-heading" id="h-performance-analysis-contrasting-strategies">Performance Analysis: Contrasting Strategies</h1>
With its impressive subscriber additions, Netflix garnered attention, surpassing expectations with 9.3 million new subscribers in the last quarter alone. The company remains bullish about its growth prospects for fiscal 2024, underpinned by strategic investments in content and advertising.
We covered Netflix Q1 earnings here: <a href="https://www.benzinga.com//node/38324337">Netflix Q1 Earnings Highlights: Revenue Beat, EPS Beat, 9.33 Million Paid Subs Added, Ad-Tier Plan Update And More</a>
In contrast, Disney is navigating a path of cost reduction, aiming to trim expenses by $7.5 billion while striving to turn its streaming business profitable by the year&#8217;s end.
Disney faces formidable challenges across its various divisions. Theme park attendance dwindles, Disney movies struggle at the box office and traditional television viewership declines. Despite the success of Disney+, its streaming platform, hurdles persist, including stagnant subscriber growth and operational inefficiencies.
<h1 class="wp-block-heading" id="h-netflix-commands-a-premium-valuation-over-disney">Netflix Commands A Premium Valuation Over Disney</h1>
Over the past year, Netflix has exhibited remarkable stock price growth, soaring by 82.97%, compared to Disney&#8217;s more modest 11.39% increase. This divergence reflects Netflix&#8217;s market dominance and investor confidence in its long-term prospects. 
Netflix commands a higher forward price-to-earnings (P/E) ratio of 30.44, indicating a premium valuation compared to Disney&#8217;s 21.66.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="650" height="450" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19083219/pe-chart.png" alt="" class="wp-image-299886" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19083219/pe-chart.png 650w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19083219/pe-chart-300x208.png 300w" sizes="(max-width: 650px) 100vw, 650px" /></figure>
Data Source: Yahoo Finance
<h1 class="wp-block-heading" id="h-analyst-sentiment-amp-future-outlook">Analyst Sentiment &amp; Future Outlook</h1>
Both stocks retain a Buy rating, albeit with varying upside potentials. While Netflix faces challenges such as growing competition and subscriber churn, Disney grapples with broader operational issues spanning its theme parks, movie studios, and television networks.
Nonetheless, Disney commands a higher upside by consensus price target.
Analysts remain cautiously optimistic about both companies&#8217; trajectories, highlighting the need for investors to carefully evaluate the risks and opportunities inherent in each stock.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="650" height="850" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19083406/consensus-chart.png" alt="" class="wp-image-299888" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19083406/consensus-chart.png 650w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19083406/consensus-chart-229x300.png 229w" sizes="(max-width: 650px) 100vw, 650px" /></figure>
Data Source: Yahoo Finance
As Netflix and Disney continue their quest for dominance in the streaming arena, investors must weigh the contrasting strategies and challenges faced by each company. 
While Netflix boasts robust financial performance and market momentum, Disney&#8217;s diversified business model and strategic initiatives offer a unique competitive edge.
Read Next: <a href="https://www.benzinga.com//node/38332511">Netflix, ON Semiconductor And Other Big Stocks Moving Lower In Friday&#8217;s Pre-Market Session</a>
Photo: Shutterstock

Long Ideas

Tech

NFLX

Understanding Netflix, Disney Market Maneuvers: Decoding The Streaming Strategy

Good Morning Traders! In today&#39;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#39;s pulse to optimize your trading gains. Now, let&#39;s dive into the stock analysis:
<h3>SPDR S&amp;P 500 ETF Trust</h3>
The SPY&nbsp;(ARCA: SPY) is currently positioned around our level of 497.55. For the bulls, an initial push above 497.55 is desired, aiming for a move to 498.17. If the price remains strong above this mark, the next target for buyers would be our support level at 498.93. A stable 498.93 during regular trading hours could set the stage for a push to 500.17.
The high target for the bulls today in SPY is set at 501.74. Conversely, if the level of 497.55 fails to hold as support, the focus shifts to the bears aiming to test the strength at 496.93. A presence of sellers could drive the price lower to 495.96. Breaking this down under heavy selling pressure could take us to a firmer support level at 494.93. A particularly rough sell-side session today might see our lowest bear target at 493.24.
<h3>Invesco QQQ Trust Series 1</h3>
The QQQ (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qqq#NASDAQ">QQQ</a>), commonly known as the Q&#39;s, is trading around a crucial level of 420.76. For the bulls, maintaining this level as support is essential, with a goal to rise to 422.16, which is hoped to be secured as a strong support. If buyers remain dominant, 423.27 could soon come into play. A robust day of buying could extend the price further to 424.04.
The ultimate bullish target for today for the Q&#39;s is 425.77. If the auction struggles to maintain above 420.76, bears may seize control and push the price down to 419.89. A display of market weakness could further depress prices to 419.19. If bearish momentum persists, we might see a drop to 418.49. Should this level not sustain, the bears could drive the price down to our lowest target of the day at 417.49.
<h3>Apple Inc.</h3>
Apple&#39;s&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) current trading level is at 167.09. For bullish traders, holding this as a base is critical, with an eye on escalating the price to 167.59. If bullish conditions prevail, we might see an increase up to 168.00. With continued control by the bulls, the target is to elevate further to our highest bull target of the day at 168.41.
If Apple cannot maintain 167.09 as a supportive level during the regular trading hours, a downward correction to 166.27 is likely. With ongoing selling pressure, the price might be pushed further down to 165.62. If this trend continues, 164.71 could be tested next. If this level fails under selling strain, bears may drive the price down to the lowest target of the day at 164.15.
<h3>Microsoft Corp.</h3>
Microsoft&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) is presently auctioning around our level of 401.39. Bulls will look to sustain this level, with aspirations to ascend to 402.74 and secure it as a strong support within regular trading hours. Maintaining this could potentially lead to a rally toward 404.92. A continuation of this momentum might elevate Microsoft to our high bull target for today at 407.11.
If 401.39 fails to hold as support, bears might initiate a downward push to 400.30. If this level capitulates, further probing might take place at 399.21. With increasing bearish pressure, the next level to test would be 398.38. Our lowest bear target for today for Microsoft stands at 397.65.
<h3>NVIDIA Corporation</h3>
NVIDIA (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>)&nbsp;is trading around a key level of 837.58. Bulls are encouraged to drive the auction upwards to 842.42, and reclaim this as a strong support zone. An upward trajectory could lead to further bullish activity targeting 846.80. A sustained buying spree could rally the price further to 852.61. The day&#39;s high bull target for NVIDIA is 858.43.
If NVIDIA fails to hold 837.58 as a strong support today, bears might look to drive the price lower to 833.50. Breaking this level down with visible seller activity could bring the auction down to 827.98. A weaker session might prompt a test at 823.52. Under persistent selling, our lowest bear target for the day is 816.95.
<h3>Alphabet Inc Class A</h3>
Alphabet&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/googl#NASDAQ">GOOGL</a>) is currently positioned around a level of 154.44. Bulls are aiming to maintain this level as support and push the auction higher to 154.95. A continuation of bullish force could escalate the auction towards our high bull target of 155.59.
If 154.44 fails to hold as a base during the regular trading hours, bears may target a lower level at 153.93. If this level is compromised, further probing to 153.54 might occur. Under intense selling pressure, the price might be driven down to our lowest bear target for Alphabet today at 152.94.
<h3>Meta Platforms Inc </h3>
Meta&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>) is currently positioned around our level of 495.54. Bulls need to ensure that this level remains strong as support, with an upward target set at 498.03. A robust buying session could push the price higher to 500.83. If bullish momentum continues, the high bull target for Meta today is set at 504.54.
If 495.54 cannot hold during regular trading hours, bears might push the price down to 492.33. Increased selling could bring further declines to 488.81. If this level does not hold, the auction could bring Meta down to our lowest bear target of the day at 485.96.
<h3>Tesla Inc.</h3>
Tesla&#39;s&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) trading action starts today around the key level of 146.46. Bulls aim to propel the price upwards to 148.45. Continued buying interest could rally the stock to 150.98. A positive broader market influence today might see Tesla reaching higher levels at 152.97. If buyer activity is strong, our high bull target for Tesla today is 155.78.
If Tesla fails to maintain 146.46 as a solid support in today&#39;s session, bears could lead a downturn to 145.07. Persistent selling might bring the price further down to 143.67. If this critical level succumbs, a price drop to our lowest bear target for the day at 141.94 could occur.
Final Word: Today&#39;s trading session is devoid of any major US data releases, which typically influence market dynamics. Attention is, however, directed toward a speech by Fed&#39;s Goolsbee, a non-voting member of the Fed, scheduled at 10:30AM ET. Although this may not directly impact market movements, it&#39;s an event to watch. Additionally, market participants will be closely monitoring the volatility associated with MOPEX and keeping an eye on developments out of the Middle East. Given the potential for significant market shifts driven by unexpected news from the Middle East, traders are advised to exercise caution. As we conclude the trading week, remain disciplined and prepared for any sudden market movements. Good luck today, let&#39;s aim to finish the week strong, and Happy Friday!
The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day&mdash;hours before it&#39;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

AAPL

GOOGL

MSFT

NVDA

TSLA

Market Clubhouse Morning Memo - April 19th, 2024 (Trade Strategy For SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, And TSLA)

Stephens &amp; Co. analyst Mason Carrico reiterates DermTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMTK#NASDAQ">DMTK</a>) with a Equal-Weight and maintains $1.5 price target.

DMTK

Stephens & Co. Reiterates Equal-Weight on DermTech, Maintains $1.5 Price Target

Barclays analyst Brandt Montour maintains Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) with a Equal-Weight and lowers the price target from $156 to $153.

Barclays Maintains Equal-Weight on Hyatt Hotels, Lowers Price Target to $153

The crypto space is fraught with opinions, with celebrities, micro-influencers and community members constantly chiming in to give their take on markets.&nbsp;
This can make it difficult for investors to determine what information is important and relevant. However, when topics are discussed by everyone, all the way up to the largest players in the space, it is likely significant. The upcoming Bitcoin halving is a great example.
Don't Miss:
<ul>
<li>If you invested $100 in DOGE when Elon Musk first tweeted about it in 2019,<a href="https://www.benzinga.com/money/etoro-doge"> here&#8217;s how much you&#8217;d have today</a>.</li>
<li>Bitcoin has jumped another 45% already this year &#8211;<a href="https://www.benzinga.com/money/kraken"> how much would you need to get started today?</a></li>
</ul>
The Bitcoin halving, an event that occurs roughly every four years, is when the amount of new tokens released each block, which typically lasts around 10 minutes, is halved. Effectively, this lowers the amount of selling pressure, as some people will instantly sell new tokens as soon as they receive them. In theory, this should provide strong upward pressure on the price. In the past, the halvings have been a catalyst for price appreciation, sending the token to new highs each time.&nbsp;
So, the halving's importance is recognized by nearly every Bitcoin enthusiast, as it has significantly impacted the price in the past. Both BlackRock and Coinbase released new blog posts and ad campaigns stressing the importance of this event.
BlackRock is the world's largest asset manager with a total of $10.5 trillion in assets under management (AUM). It was also one of the firms that released a spot Bitcoin exchange-traded fund (ETF) in January, with its ETF trading under the name IBIT. The ETF has been the most successful of the ETFs, attracting over $17 billion in investment.&nbsp;
Trending: Dogecoin millionaires are increasing —<a href="https://www.benzinga.com/money/dogecoin-millionaires-adv"> investors with $1M+ in DOGE revealed!</a>
In <a href="https://www.ishares.com/us/insights/what-is-the-bitcoin-halving">a blog post</a> earlier this week, Jay Jacobs, BlackRock's head of Thematic and Active ETFs, said, "Historically, Bitcoin performance has been positive leading into and in the year of and immediately following halving events" but also that "each subsequent halving has had a smaller impact on Bitcoin's inflation schedule. With about 94% of all Bitcoin already mined, future issuance represents a small fraction of the circulating supply, potentially reducing the comparison to historical halving events. Moreover, Bitcoin has been around since only 2009, so a sample size of just three prior halvings makes it difficult to place confidence in the accuracy of this narrative."
The blog post described what the halving entails and the historical impacts, ultimately calling investors to take a closer look at the IBIT ETF and consider investing.
Coinbase also released an <a href="https://twitter.com/coinbase/status/1779902729860591745">ad campaign</a> surrounding the halving. The ad shows how many pizzas can be purchased with one Bitcoin, starting with one in 2012 and leading up to a mound of pizzas in 2024. The ad states that "roughly every four years, the future supply of Bitcoin is reduced. So historically, you get more, not less." The ad has an interesting take on the visual representation of Bitcoin's price increases, ultimately stating that "Bitcoin moves money forward."&nbsp;
The halving is undeniably an important event for Bitcoin. This was made apparent through large companies putting huge investments into spreading the word about the halving and calling for investment. With the halving expected to occur today, it will be interesting to see how the price of Bitcoin will react.&nbsp;
Read Next:
<ul>
<li>About 22% of the adult population in the U.S. own a share of Bitcoin,<a href="https://www.benzinga.com/money/kraken"> how much would $10 get you today</a>?</li>
<li>The<a href="https://www.benzinga.com/money/kraken-2"> last-standing top crypto exchange without a major security breach</a> offers what now?</li>
</ul>
<figure class="wp-block-image aligncenter size-full"><a href="https://www.benzinga.com/events/digital-assets"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/28172612/905735A6-57D3-4874-9AA1-75D037842DB3.gif" alt="crypto digital assets" class="wp-image-269852" /></a></figure>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

BlackRock And Coinbase Explain Importance Of Bitcoin Halving In New Ad Campaigns

Legendary investor Warren Buffett offered straightforward <a href="https://www.benzinga.com/personal-finance/24/04/38275323/warren-buffett-warns-dont-watch-the-market-closely-urges-not-to-obsessively-check-stock-prices-i">investment advice</a> during an appearance, on CNBC's "Squawk Box," which followed the release of Berkshire Hathaway Inc.'s annual shareholder letter. Buffett's advice centered on an investment <a href="https://www.benzinga.com/personal-finance/24/04/38020981/warren-buffetts-first-wife-said-he-cared-about-the-win-never-about-money-everybody-can-read-what">strategy for his wife</a>, Astrid, guided by the instructions he had laid out in his will.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich-advisor">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
</ul>
In the interview, he said the Berkshire shares would <a href="https://www.benzinga.com/general/24/04/38253754/warren-buffett-charity-lunch-auction-is-no-more-the-ceo-who-will-replace-legendary-investor-in-this">go to philanthropy</a>. Part of the cash would go directly to his wife and part to a trustee. He told the trustee to put 10% of the cash in short-term government bonds and 90% in a low-cost S&amp;P 500 index fund.
CNBC's Becky Quick highlighted that it was the first time Buffett had publicly discussed the details. Buffett said, "I laid out what I thought the average person who is not an expert on stocks should do. And my widow will not be an expert on stocks. I want to be sure she gets a decent result."
The strategy Buffett outlined is not just for his family but applies to any investor seeking reliable returns without the need for expert knowledge. He advised using the 10% allocation in short-term government bonds as a buffer during market downturns, allowing for withdrawals without needing to sell stocks at potentially low prices.
The S&amp;P 500 index encompasses a broad range of stocks, including major companies such as Apple Inc., Microsoft Corp. and Google parent Alphabet Inc. The appeal of index funds lies in their passive investment strategy, which involves low turnover rates. This efficiency helps to keep fees and taxes low.&nbsp;
Trending: The average American couple has saved this much money for retirement <a href="http://www.benzinga.com/money/smartasset">— How do you compare</a>?
The performance of index funds is tied to the results of the companies in them, providing a balanced investment as gains in some stocks can offset losses in others. For instance, if one company's stock in the index rises by 3% and another falls by 2%, the net increase would be 1%, thereby offering a simplified and effective approach to investing in the broader market.
Buffett has long advocated for the benefits of index funds, highlighting his views as early as the 1993 annual shareholder letter.&nbsp;
"By periodically investing in an index fund, for example, the know-nothing investor can actually outperform most investment professionals," he wrote in the letter. "Paradoxically, when ‘dumb' money acknowledges its limitations, it ceases to be dumb."
Trending: Americans got swindled out of $24.6 billion in the last 3 years —<a href="https://www.benzinga.com/money/advisor-adv"> Which high profile ponzi scheme was endorsed by millionaires?</a>
Buffett's endorsement of index funds continued in the 2016 shareholder letter, where he shared insights gained from decades of giving investment advice. He consistently recommended a low-cost S&amp;P 500 index fund, observing that wealthy people often believe their money should buy them access to superior investment options.&nbsp;
Buffett criticized this mindset, noting that the financial "elites" struggle to accept that a product beneficial to both small and large investors could be the optimal choice. He explained that this reluctance often leads to significant financial waste, estimating that the quest for exclusive investment advice has cost the elite over $100 billion in the past decade.
Buffett&#8217;s insight provides a foundation for long-term investing, but the financial world can still feel complex, especially for beginners. The ever-changing market and the vast array of options can be overwhelming, which is why <a href="https://www.benzinga.com/money/smartasset">consulting a qualified financial adviser</a> is beneficial. They can tailor Buffett&#8217;s core principles — like low-cost index funds and diversification — to your unique circumstances and risk tolerance. Even the savviest investors benefit from a second set of eyes. 
Read Next:
<ul>
<li>How to turn a $100,000 investment into $1 Million — and<a href="https://www.benzinga.com/money/fam"> retire a millionaire.</a></li>
<li>If the United States had access to<a href="https://www.benzinga.com/money/public-hys-avgamerican"> today&#8217;s high-yield savings accounts rates</a> in 2015, it wouldn&#8217;t need to save another penny.</li>
</ul>

Personal Finance

Warren Buffett Reveals The Instructions In His Will To Invest 90% Of Wife's Inheritance — 'My Widow Will Not Be An Expert On Stocks'

Fed's Goolsbee Says Not All Data Suggest Labor-Market Overheating; Fed Has To Recalibrate,'Wait And See' On Inflation

Stephens &amp; Co. analyst Andrew Terrell reiterates Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) with a Overweight and maintains $82 price target.

Stephens & Co. Reiterates Overweight on Western Alliance, Maintains $82 Price Target

Barclays analyst Christine Cho maintains First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Overweight and raises the price target from $224 to $227.

FSLR

Barclays Maintains Overweight on First Solar, Raises Price Target to $227

Taylor Swift's blockbuster Eras Tour combined with the value of her music catalog propelled the pop star to the ranks of billionaire in October.
Although her undeniable talent is a big piece of how she landed in the upper echelon of wealth, Swift's business acumen is what put her over the top. Swift strategically diversified her portfolio, capitalizing on various revenue streams. Her savvy investments in real estate, technology and brand partnerships all contributed to her financial success.
Since 2011, Swift has amassed a real estate portfolio valued at more than $125 million. Take a look at the properties she owns.
Don't Miss:
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
<h2 class="wp-block-heading">New York City</h2>
Swift ventured into the New York City market in 2014 when she paid $19.95 million for two adjacent penthouses in the Tribeca neighborhood. She has since acquired nearly the entire block, buying the second floor of the building for almost $10 million in 2018.
In 2017, she bought a 100-year-old townhouse next door for $18 million. The seven-bedroom, six-bath, three-story residence came with a gym, spa and wide-plank oak floors. Swift has applied for permits and work orders for more than $1 million of renovations to the property.
Trending
<ul>
<li>Want to Create a Passive Income Stream? <a href="https://www.benzinga.com/go/grow-wealth-passively">These High-Yield Real Estate Notes Might Be Your Holy Grail</a></li>
</ul>
<h2 class="wp-block-heading">Watch Hill, Rhode Island</h2>
Swift paid $17.75 million in cash for a 12,000-square-foot Rhode Island home on 5 acres with more than 700 feet of beachfront on the highest point in Watch Hill. The house has eight bedrooms and eight fireplaces.
<h2 class="wp-block-heading">Nashville, Tennessee</h2>
Swift, 34, made one of her first real estate purchases on Nashville's Music Row when she was 20. She paid $1.9 million for a 3,240-square-foot three-bedroom corner duplex at the Adelicia complex, which has a heated Olympic-length pool and personal trainer.
In June 2011, Swift bought Northumberland Estate for $2.5 million. The 5,600-square-foot main house and 2,000-square foot guest house are on 6 acres in Nashville's exclusive Forest Hills suburb.
<h2 class="wp-block-heading">Los Angeles and Beverly Hills, California</h2>
Swift has bought and sold a few of her California residences — the first for $4 million and the other, which she used as a guesthouse, for $2.65 million.
She still owns one property in LA, a 1934 Georgian Revival estate she purchased in 2015 for $25 million. The 10,982-square-foot home has seven bedrooms and eight bathrooms. The Beverly Hills Cultural Commission recently approved turning the home, once owned by Hollywood film producer Samuel Goldwyn, into a historic landmark.
From historic mansions to sleek modern penthouses, Swift has curated a collection of properties that reflect her keen eye for investments and solidify her status as a savvy businesswoman.
&nbsp;Read Next:
<ul>
<li>Elon Musk Is Bullish On Austin. Here&#8217;s <a href="https://www.benzinga.com/go/musk-austin">How To Invest In The City&#8217;s Growth Before He Floods It With New Tech Workers</a>.</li>
<li>Whole Foods&#8217; Landlord Has Achieved A 15% Net IRR For Accredited Investors Since 2015 — <a href="https://www.benzinga.com/go/whole-foods-landlord">Discover The Latest Investment Opportunities On Its Platform</a>. </li>
</ul>

Real Estate

How Real Estate Helped Taylor Swift Become A Billionaire

Fed's Goolsbee Says Will Take Longer To Get Inflation Down To 2% Goal

UBS analyst A.J. Rice maintains Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) with a Buy and raises the price target from $585 to $605.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

UBS Maintains Buy on Elevance Health, Raises Price Target to $605

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the trading week with a look at the biggest pre-market stock movers for Monday morning!



Moving stocks this morning are earnings reports, clinical trial results, proposed public offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Jet AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/jtai-stock-quote/">JTAI</a>) stock is rocketing more than 48% alongside heavy pre-market trading.</li>



<li>NextPlay Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxtp-stock-quote/">NXTP</a>) shares are soaring over 43% with strong early morning trading.</li>



<li>Virco Manufacturing (NASDAQ:<a href="https://investorplace.com/stock-quotes/virc-stock-quote/">VIRC</a>) stock is surging more than 23% alongside its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317916866&amp;type=PDF&amp;symbol=VIRC&amp;cdn=3ac20704c37a39535cbe11e419334e5a&amp;companyName=Virco+Manufacturing+Corporation&amp;formType=10-Q&amp;formDescription=General+form+for+quarterly+reports+under+Section+13+or+15%28d%29&amp;dateFiled=2023-12-08">latest earnings report</a>.</li>



<li>Poseida Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/pstx-stock-quote/">PSTX</a>) shares are gaining over 23% with the release of <a href="https://www.nasdaq.com/press-release/poseida-therapeutics-presents-positive-early-results-from-its-phase-1-trial-of">Phase 1 clinical trial results</a>.</li>



<li>Macy&rsquo;s (NYSE:<a href="https://investorplace.com/cryptocurrency/m/">M</a>) stock is rising close to 20% on <a href="https://finance.yahoo.com/news/macys-mulling-58-billion-buyout-offer-source-230606275.html">reports of a buyout offer</a>.</li>



<li>Onconova Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ontx-stock-quote/">ONTX</a>) shares are increasing more than 19% with the release of <a href="https://www.nasdaq.com/press-release/onconova-therapeutics-preclinical-narazaciclib-data-at-sabcs-highlights">new preclinical study data</a>.</li>



<li>Charge Enterprises (NASDAQ:<a href="https://investorplace.com/stock-quotes/crge-stock-quote/">CRGE</a>) stock is climbing nearly 15% despite a lack of news this morning.</li>



<li>AcelRx Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/acrx-stock-quote/">ACRX</a>) shares are heading over 14% higher without any clear news on Monday.</li>



<li>Allbirds (NASDAQ:<a href="https://investorplace.com/stock-quotes/bird-stock-quote/">BIRD</a>) stock is jumping more than 14% this morning.</li>



<li>ProShares UltraShort Bloomberg Natural Gas (NYSEARCA:<a href="https://investorplace.com/stock-quotes/kold-stock-quote/">KOLD</a>) shares are up over 13% alongside <a href="https://www.wsj.com/finance/commodities-futures/natural-gas-futures-rise-on-bullish-storage-draw-c5a08a65">struggling natural gas prices</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Green Giant (NASDAQ:<a href="https://investorplace.com/stock-quotes/gge-stock-quote/">GGE</a>) stock is plummeting more than 40% after announcing a <a href="https://www.nasdaq.com/press-release/green-giant-inc.-announces-proposed-public-offering-2023-12-08">proposed public offering</a>.</li>



<li>RiskOn International (NASDAQ:<a href="https://investorplace.com/stock-quotes/roi-stock-quote/">ROI</a>) shares are diving over 32% without any clear news this morning.</li>



<li>Near Intelligence (NASDAQ:<a href="https://investorplace.com/stock-quotes/nir-stock-quote/">NIR</a>) stock is tumbling more than 27% with <a href="https://www.nasdaq.com/press-release/near-intelligence-files-for-chapter-11-protection-and-enters-into-agreement-to-sell">a Chapter 11 filing</a>.</li>



<li>African Agriculture (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAGR#NASDAQ">AAGR</a>) shares are taking an over 24% beating <a href="https://www.marketwatch.com/story/african-agriculture-shares-down-45-in-second-day-of-trading-following-spac-merger-c54f6378">after recently going public</a>.</li>



<li>iSun (NASDAQ:<a href="https://investorplace.com/stock-quotes/isun-stock-quote/">ISUN</a>) stock is sliding more than 16% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317917809&amp;type=PDF&amp;symbol=ISUN&amp;cdn=ea064c9c7d6b8dc4f8255775df56f986&amp;companyName=iSun+Inc.&amp;formType=S-3&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2023-12-08">proposed public share offering</a>.</li>



<li>X4 Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/xfor-stock-quote/">XFOR</a>) shares are dropping over 16% after presenting <a href="https://finance.yahoo.com/news/x4-pharmaceuticals-announces-presentation-additional-170000113.html">additional data from a clinical trial</a>.</li>



<li>Purple Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/ppbt-stock-quote/">PPBT</a>) stock is decreasing more than 15% on Monday morning.</li>



<li>Argo Blockchain (NASDAQ:<a href="https://investorplace.com/stock-quotes/arbk-stock-quote/">ARBK</a>) shares are slipping almost 14% this morning.</li>



<li>ProShares Ultra Bloomberg Natural Gas (NYSEARCA:<a href="https://investorplace.com/stock-quotes/boil-stock-quote/">BOIL</a>) stock is dipping over 13% today.</li>



<li>Science 37 (NASDAQ:<a href="https://investorplace.com/stock-quotes/snce-stock-quote/">SNCE</a>) shares close out our pre-market stock movers down more than 12%.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT766529">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-dec-11th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

PPBT, ANY and FLJ among pre-market losers

Purple Biotech stock climbs 9% on Phase 2 study update

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Purple Biotech (PPBT – Research Report) and Sanofi (...

Analysts Offer Insights on Healthcare Companies: Purple Biotech (PPBT) and Sanofi (OtherSNYNF)

The market has been high on Purple Biotech Ltd - ADR (PPBT)  stock recently. PPBT gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Purple Biotech Ltd - ADR has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on PPBT!See Full PPBT ReportWhat is Stock Senti

Purple Biotech Ltd - ADR (PPBT) Stock: What Does the Chart Say Friday?

Purple Biotech (PPBT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C...

Buy Rating Justified by Promising Phase 1 Results of Purple Biotech's NT219 in SCCHN Treatment

Purple Biotech GAAP EPADS of -$0.19

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Purple Biotech (PPBT – Research Report), with a price target of $10.00. Emily Bo...

Promising Pipeline Prospects for Purple Biotech: Buy Rating Affirmed Amidst Anticipated Clinical Advancements

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Purple Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/ppbt-stock-quote/">PPBT</a>) just reported results for the fourth quarter of 2023.<ul><li>Purple Biotech reported earnings per share of -19 cents. This met the analyst estimate for EPS of -19 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/ppbt-stock-earnings-purple-biotech-for-q4-of-2023/">PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023

Purple Biotech Ltd. (PPBT) has released an update. Purple Biotech Ltd. has announced exciting developments for its cancer drug NT219, revealing its...

Purple Biotech's NT219 Shows Promising Cancer Fight

ARBK

BIRD

BITF

BKKT

BOIL

BTBT

BTDR

CLSK

COGT

CRGE

FTCH

GDHG

JTAI

KOLD

MIGI

MLGO

PBTS

PSTX

RIOT

SNCE

SNYNF

SOAR

SVFD

VERU

VIRC

WULF

Legal

Press Releases

Purple Biotech Fortifies NT219 Patent Protection

Earnings

Purple Biotech Reports Third Quarter 2023 Financial Results

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Management

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology